Most obesity medicine literature focuses on GLP-1 monotherapy or dual-peptide protocols (semaglutide plus tirzepatide), which show superior long-term efficacy and safety profiles without the cardiovascular burden of sympathomimetic agents
20 We assessed the risk of bias for randomization process, deviations from intended interventions, missing outcome data, measurement of outcome, selection of reported results, and other biases
Two differents versions were designed in Tableau for giving feedback of the results to patients and health professionals
Smith, L.C., Hawley, T.S., Henson, J.H., Majeske, A.J., Oren, M
Unfortunately, many species are decreasing in population, and some have become extinct (IUCN, 2022)